Products - Inflammatory bowel disease | Topic | NICE

Showing 3 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 August 2025
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 August 2025
Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC